Pristiq (desvenlafaxine succinate sustained-release) fails again in second phase III trial for depression- Pfizer
Pfizer announced the top line results from a Phase III study which evaluated the efficacy, safety, and tolerability of Pristiq (desvenlafaxine succinate sustained-release) in pediatric patients ages 7 to 17 with Major Depressive Disorder (MDD). The study did not meet its primary objective to demonstrate superior efficacy of desvenlafaxine succinate sustained-release formulation compared to placebo. Desvenlafaxine did not demonstrate superior efficacy compared to placebo in either study. Efficacy results indicate that both desvenlafaxine succinate sustained-release formulation low dose exposure and high dose exposure treatment arms were not statistically significantly different from placebo.
There were no new safety signals identified. Adverse events occurring after the start of treatment in the desvenlafaxine succinate sustained-release formulation group were generally consistent with those observed in both the Phase 2a pediatric MDD safety studies and the studies of desvenlafaxine succinate sustained-release formulation-treated adults with MDD. This is the second of two Phase III placebo controlled studies conducted as part of an FDA post-marketing commitment under the Pediatric Research Equity Act (PREA).
Related news and insights
Gilead Sciences, Inc. announced the FDA has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP).
Bristol Myers Squibb announced the Phase III CheckMate -901 trial, comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to standard-of-care chemotherapy as a first-line treatment for patients with untreated unresectable or metastatic urothelial carcinoma, did not meet the primary endpoint of overall survival (OS) in patients whose tumor cells express PD-L1 greater than 1% at final analysis.